Charles D. Wells - Concepedia

Author

Charles D. Wells

Centers for Disease Control and Prevention

Also Known As

Andra Cirule, C D Wells, C Wells, C. D. Wells, C.D. Wells, CHARLES D. WELLS, Charles D Wells, Charles D. Wells, Charles Wells, Charles D. Wells

Publications

7.1K

Citations

H-Index

Concepts

All Affiliations

Centers for Disease Control and Prevention Ministry of Public Health Tartu University Hospital Otsuka (United States)Botho University

About

Charles D. Wells is an author at Centers for Disease Control and Prevention specializing in medicine, tuberculosis, and drug resistance.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	16	2.4K
2	Health Sciences	6	6	1.1K
3	Public Health	6	6	1.3K
4	Social Sciences	1	1	106
5	Emergency Medicine	1	1	28

Charles D. Wells

Publications

6.3K

Citations

H-Index

Page 1

	Year	Citations
Delamanid for Multidrug-Resistant Pulmonary Tuberculosis Maria Tarcela Gler, Vija Skripconoka, Epifanio Sànchez-Garavito, New England Journal of Medicine	2012	731
Worldwide Emergence of Extensively Drug-resistant Tuberculosis Neha Shah, A Wright, Gill‐Han Bai, Emerging infectious diseases Pulmonary TuberculosisWorldwide EmergenceHealth SciencesTuberculosis PreventionPharmacology	2007	581
Global epidemiology of childhood tuberculosis. L J Nelson, Charles D. Wells PubMed Pulmonary TuberculosisPediatric EpidemiologyGlobal HealthTuberculosis PreventionClinical Epidemiology	2004	461
6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial Taraz Samandari, Tefera Agizew, Samba Nyirenda, The Lancet Pulmonary TuberculosisTreatment And PreventionTuberculosis PreventionHiv InfectionTuberculosis	2011	356
Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis Vija Skripconoka, Manfred Danilovitš, Lea Pehme, European Respiratory Journal	2012	336
Tobramycin Solution for Inhalation Reduces Sputum <i>Pseudomonas aeruginosa</i> Density in Bronchiectasis Alan F. Barker, Leslie Couch, Stanley B. Fiel, American Journal of Respiratory and Critical Care Medicine	2000	335
Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis Mohamed Abdel Aziz, A Wright, A László, The Lancet Antituberculosis Drug ResistancePulmonary TuberculosisDrug Resistance AnalysisHealth SciencesGlobal Project	2006	325
Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study Vaira Leimane, Vija Riekstiņa, Timothy H. Holtz, The Lancet Multidrug-resistant TuberculosisPulmonary TuberculosisIndividualised TreatmentGlobal HealthTuberculosis Prevention	2005	271
Time to Sputum Culture Conversion in Multidrug-Resistant Tuberculosis: Predictors and Relationship to Treatment Outcome Timothy H. Holtz, Maya Sternberg, Steve Kammerer, Annals of Internal Medicine	2006	230
Isoniazid, Rifampin, Ethambutol, and Pyrazinamide Pharmacokinetics and Treatment Outcomes among a Predominantly HIV‐Infected Cohort of Adults with Tuberculosis from Botswana Sekai Chideya, Carla A. Winston, Charles A. Peloquin, Clinical Infectious Diseases	2009	228

Page 1